Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CST-2032 in Mild Cognitive Impairment and Parkinson's Disease
NCT05033912Phase 1Withdrawn
- Sponsor
- CuraSen Therapeutics
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of CST-2032 in Mild Cognitive Impairment (MCI) and Parkinson's disease (PD) (4 arms), sponsored by CuraSen Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events, Vital Signs and 1 more. Planned start Oct 2021; status: withdrawn.
02
Drugs
CST-2032
03
Conditions
Mild Cognitive Impairment (MCI)Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05033912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05033912.